Pfizer and AstraZeneca: What Would a Combined Company Offer?


From DCAT Value Chain Insights (VCI)

By Patricia Van Arnum posted 04-29-2014 14:02

  
Pfizer confirmed this week it had earlier discussions in January with AstraZeneca for a proposed merger transaction valued at nearly $100 billion, but AstraZeneca has said thus far it is not interested.

 
Ian Read
Chairman and CEO
Pfizer
Pfizer confirmed this week (see related story, “Pfizer Confirms Interest in Merging with AstraZeneca”) that it had been in initial discussion with AstraZeneca in January 2014 over a possible combination of the companies and that it still has interest in acquiring AstraZeneca. Pfizer had made a non-binding proposal of interest to the board of AstraZeneca on January 5, 2014 for a combination of cash and shares in the combined entity that represented an indicative value of £46.61 ($76.62) per AstraZeneca share or approximately $100 billion, an initial proposal that was rejected by AstraZeneca. To date, as recently as late April, AstraZeneca has said it plans to stay an independent company and has declined Pfizer’s overtures. Pfizer has until May 26 to make a firm bid or confirm that it does not plan to bid for AstraZeneca. As the waiting game begins, what are the key strengths of a combined Pfizer/AstraZeneca product portfolio and what would a combined manufacturing network be?

A Combined AstraZeneca and Pfizer
In a press statement, Pfizer Chairman and CEO Ian Read outlined the benefits of a proposed combination between the two companies. “A potential combination with AstraZeneca aligns with Pfizer’s current structure and fully supports its existing strategy to build world-class businesses. The combination would complement our two innovative businesses and our Global Established Pharmaceutical business, allowing us to maintain the flexibility for the potential future separation of our businesses whilst at the same time broadening our pipeline breadth and potential new product launches over coming years. We believe that a transaction would further strengthen our ability to generate strong and consistent cash flow, targeted for both investment in our business and return to shareholders while at the same time offering an efficient operating structure and the anticipated realization of attractive synergies.”

Pfizer outlined the companies’ respective contribution from their current product portfolios and pipelines for innovative products as well as for established products based on Pfizer’s current business structure: the Global Innovative Pharmaceutical business, the Global Vaccines, Oncology and Consumer Healthcare business, and the Global Established Pharmaceutical business (see Tables I–III). Table I outlines the key therapeutic areas and related synergies in what Pfizer deems as its Global Innovative Pharmaceutical business, which consists of medicines within several therapeutic areas that Pfizer generally expects to have market exclusivity beyond 2015. These therapeutic areas include immunology and inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health. Table II outlines the key product contributions in a proposed Pfizer and AstraZeneca combination in Pfizer’s Global Vaccines, Oncology and Consumer Healthcare business, which focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. Within Pfizer, each of the three businesses that comprise this group operates as a separate, global business, with distinct specialization in terms of the science, talent, and market approach necessary for that area. Table III outlines the key focus in a proposed combination of the two companies in established or mature products. Pfizer’s Global Established Pharmaceutical business includes the brands that have lost market exclusivity and, generally, the mature, patent-protected products that are expected to lose exclusivity through 2015 in most major markets and, to a much smaller extent, generic pharmaceuticals. Additionally, it includes sterile injectable products and Pfizer’s biosimilar development portfolio, as well as current established product collaborations, such as Pfizer’s existing agreements with Mylan Inc. in Japan, Zhejiang Hisun Pharmaceutical Co. Ltd. in China, and Laboratório Teuto Brasileiro S.A. in Brazil.



  Table I: Proposed Combination of AstraZeneca and Pfizer, Global Innovative  
  Pharmaceuticals, Portfolio and Pipeline.



 Therapeutic Area  Pfizer  AstraZeneca
 Inflammation & Immunology  Xeljanz (tofacitinib  
 citrate)
 Lesinurad*

 Enbrel (etanercept)  Brodalumab*

 PD-0360324  Mavrilimumab 

 PF-00547659  MEDI-2070
   PF-04171327  MEDI-546

 PF-04236921  MED-7183

 PF-05285401  Sifalimumab
   PF-06473871  RDEA3170
   PH-797804  

 Therapeutic Area  Pfizer  AstraZeneca
 Cardiovascular / Metabolics  Eliquis (apixaban)  Brilinta (ticagrelor)

 Chantix (varenicline 
 tartrate)
 Onglyza (saxagliptin 
 hydrochloride)

 Bococizumab*  Bydureon (exenatide 
 extended-release for 
 injectable suspension) 

 PF-00489791  Forxiga (dapagliflozin)
   PF-04634817  Myalept (metreleptin)

 PF-04937319  Epanova 
 (eicosapentaenoic acid
 and docosahexaenoic 
 acid)*


 PF-05175157  Roxadustat*
     AZD-1722
     AZD-4901

 Therapeutic Area  Pfizer  AstraZeneca
 Neuro / Pain  Lyrica (pregabalin),
 ex-EU
Naloxegol*

 Embeda (morphine 
 sulfate and naltrexone 
 hydrochloride)
AZD-3241

 Flector (diclofenac 
 epolamine)
AZD-5213

 Remoxy (oxycodone)*
   ALO-02*

 Tanezumab*

 PF-02545920
   PF-04360365
   PF-05212377  

 Therapeutic Area  Pfizer  AstraZeneca
 Rare Diseases & Specialty 
 Care
 Genotropin (somatropin 
 recombinant)
Synagis (palivizumab)

 Benefix (coagulation 
 Factor IX recombinant)
AZD-5847

 Refacto (antihemophilic 
 factor recombinant)


 Rebif (interferon
 beta-1A)

   Rapamune (sirolimus)

 Elelyso (taliglucerase 
 alfa)


 Tafamidis*
   Rivipansel

 Therapeutic Area  Pfizer  AstraZeneca
 Women’s & Men’s Health  Viagra (sildenafil citrate) US

 Duavee (bazedoxifene 
 acetate; estrogens 
 conjugated) 


 Toviaz (fesoterodine 
 fumarate)


 Viviant (bazedoxifene)

*Note: Phase III and registration programs denoted by asterisk. Only includes select commercial and development programs. Excludes respiratory and infectious disease assets (which are included as part of Global Established Products), see Table III. 

Source: Pfizer

 
Crunching the numbers
Pfizer. In 2013, Pfizer reported sales of pharmaceuticals/biopharmaceuticals of $47.9 billion, down 7% compared to 2012, according to the company’s annual filing (1). It had 10 products with sales of more than $1 billion, which when combined, accounted for 51% of its revenues from biopharmaceuticals/pharmaceuticals. These products were: the neuropathic pain/anticonvulsant drug Lyrica (pregabalin), 2013 sales of $4.595 billion; the Prevnar (pneumococcal 7-valent conjugate vaccine) family of products, 2013 sales of $3.974 billion; the anti-arthritis drug Enbrel (etanercept), 2013 sales of $3.744 billion; the nonsteroidal anti-inflammatory drug Celebrex (celecoxib), 2013 sales of $2.918 billion; the anticholesterol drug Lipitor (atorvastatin calcium), 2013 sales of $2.315 billion; the erectile dysfunction drug Viagra (sildenafil citrate), 2013 sales of $1.881 billion; the antibacterial drug Zyvox (linezolid), 2013 sales of $1.353 billion; the antihypertensive drug Norvasc (amlodipine), 2013 sales of $1.229 billion; the anticancer drug Sutent (sunitinib malate), 2013 sales of $1.204 billion; and the Premarin (conjugated estrogens) family of products used in hormone-replacement therapy, 2013 sales of $1.092 billion (1).

Pfizer’s 2013 revenues were affected by several key factors. In the US, revenues from biopharmaceutical/pharmaceutical products decreased 6% in 2013, compared to 2012, reflecting, among other things: lower revenues from Lipitor, the antihypertensive drug Revatio (sildenafil), and the antipsychotic drug Geodon(ziprasidone), all due to loss of exclusivity (down approximately $875 million in 2013); lower alliance revenues from the respiratory drug Spiriva (tiotropium bromide inhalation powder), reflecting the final-year terms of its Spiriva co-promotion agreement in the US (down approximately $320 million in 2013), and Enbrel, reflecting the expiration of the co-promotion agreement in the US and Canada in October 2013 (down approximately $82 million); lower revenues from generic atorvastatin (down approximately $145 million in 2013); lower revenues from Prevnar due to decreased government purchases (down approximately $84 million in 2013); and lower revenues from the antibacterial drug Zosyn (piperacillin and tazobactam) (down approximately $45 million in 2013). These losses were partially offset by other gains: the strong performance of certain other  products, including Lyrica, Celebrex, the anti-arthritis drug Xeljanz (tofacitinib), the anticancer drug Inlyta (axitinib), and the anticancer drug Xalkori (crizotinib) (up approximately $715 million in 2013) (1).

In international markets, revenues from pharmaceutical/biopharmaceutical products decreased 7% in 2013, compared to 2012. Operationally, revenues decreased 3% in 2013, compared to 2012, with several key factors playing a role: lower revenues for Lipitor and the eye-care drug Xalatan (latanoprost opthalmic solution/Xalacom (latanoprost/timolol) (down approximately $1.4 billion in 2013) due to the loss of exclusivity of Lipitor in developed Europe, Japan, and Australia, and Xalatan/Xalacom in the majority of European markets and in Australia; lower revenues for Viagra (down approximately $108 million in 2013) primarily due to loss of exclusivity in most major markets in Europe; and lower revenues for the Alzheimer's drug Aricept (donepezil) (direct sales) (down approximately $88 million in 2013) due to the loss of exclusivity in certain markets and lower alliance revenues (down approximately $493 million in 2013), primarily due to the loss of exclusivity of Aricept in many major European markets, the return of its rights to Aricept in Japan to Eisai Co., Ltd.; and lower revenues for Spiriva in certain European countries, Canada, and Australia (where the Spiriva collaboration has terminated). These losses were partially offset by higher revenues for Lyrica, and new product growth from Inlyta and Xalkori (collectively, approximately $506 million in 2013) (1).

Pfizer’s consumer healthcare business posted 2013 sales of $3.3 billion, up 4% from 2012. In August 2012, Pfizer formed an agreement with AstraZeneca for the exclusive, global, over-the-counter (OTC) rights for Nexium (esomeprazole), AstraZeneca’s prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease. Pfizer made an upfront payment of $250 million to AstraZeneca, and AstraZeneca is eligible to receive milestone payments of up to $550 million based on product launches and level of sales as well as royalty payments based on sales. In August 2013, the European Commission granted a marketing authorization for Nexium Control OTC, with non-prescription status in all EU member states for the short-term treatment of reflux symptoms (including heartburn and acid regurgitation in adults). FDA approved an OTC version, Nexium® 24HR (esomeprazole 20mg) in late March 2014 (1). 



  Table II: Proposed Combination of AstraZeneca and Pfizer Vaccines,
  Oncology, and Consumer Health, Portfolio and Pipeline



 Therapeutic Area  Pfizer  AstraZeneca
 Vaccines  Prevnar (pneumococcal 
 7-valent conjugate)
FluMist(influenza vaccine
live)

 MNB vaccine*  FluMist Quadrivalent 
 (influenza vaccine live)

 Staph A vaccine  

 Therapeutic Area  Pfizer  AstraZeneca
 Oncology  Sutent (sunitinib malate)  Faslodex (fulvestrant)

 Xalkori (crizotinib)  Iressa (gefitinib)

 Inlyta (axitinib)  Caprelsa (vandetanib) 

 Bosulif (bosutinib)  Moxetumomab*
   Torisel (temsirolimus)  Olaparib*

 Palbociclib*  Selumetinib*

 PF-03446962  AZD-9291*
   PF-05212384  Tremelimumab
   PF-04449913  AZD-4547
   PD-0325901  MEDI-551
   PF-03084014  AZD-1775
   PF-05082566  MEDI-4736
   PF-06263507  AMP-514
   PF-0643922  MEDI-6469
     AZD-5363
     AZD-2014
     MEDI-573

 Therapeutic Area  Pfizer  AstraZeneca
 Consumer Health  Advil (ibuprofen)

 Caltrate (calcium 
 supplement)

 Centrum 
 (vitamins/supplements)

 ChapStick (lip balm)
   Emergen-C (Vitamin C 
 (ascorbic acid) mix)


 Imedeen (oral skin care tablets)

 Nexium OTC 
 (esomeprazole 
 magnesium)

   Robitussin (cough medicine)

*Note: Phase III and registration programs denoted by asterisk. Only includes select commercial and development programs. Excludes respiratory and infectious disease assets (which are included as part of Global Established Products), see Table III. 

Source: Pfizer

AstraZeneca. AstraZeneca posted 2013 sales of $25.711 billion, down 6% (reported in constant exchange rates) compared to 2012, according to the company’s annual filing (2). Its top 10 products accounted for 75% of the company sales, which included five products with sales of more than $1 billion. The company’s top 10 products in 2013 were: the anticholesterol drug Crestor (rosuvastatin calcium), 2013 sales of $5.622 billion; the acid-reflux drug Nexium (esomeprazole magnesium), 2013 sales of $3.872 billion; the respiratory drug Symbicort (budesonide/formoterol fumarate dihydrate), 2013 sales of $3.483 billion; the antidepressant Seroquel (quetiapine fumarate), 2013 sales of $1.337 billion; Synagis (palivizumab),a drug to prevent respiratory syncytial virus, 2013 sales of $1.060 billion; the anticancer drug Zoladex (goserelin), 2013 sales of $996 million; the respiratory drug Pulmicort (budesonide), 2013 sales of $867 million; the antihypertensive drug Seloken/Toprol-X (metoprolol), 2013 sales of $750 million; the anticancer drug Faslodex (fulvestrant), 2013 sales of $681 million; and the anticancer drug Iressa (gefitinib), 2013 sales of $647 million, according to the company’s 2013 annual filing (2). Of these 10 drugs, three reported sales declines in 2013: Seloken/Toprol-X (-18%), Seroquel XR (-12%), and Crestor (-8%). Sales of Nexium and Zoladex were flat year over year, and five of the top 10 drugs reported sales gains in 2013 over 2012: Iressa (+11%), Symbicort (+10%), Faslodex (+6%), Synagis (+2%), and Pulmicort (+1%) (2). 

R&D
Pfizer. In 2013, Pfizer spent $6.7 billion on R&D, down from $7.5 billion in 2012 and $8.7 billion in 2011. As of year-end 2013, Pfizer had 279 projects in R&D, ranging from discovery through registration, of which 81 programs were in Phase I through registration, with the remainder of the projects in preclinical development. At year-end 2013, the company’s Phase III portfolio contained 20 programs. Its research primarily focuses on five high-priority areas that have a mix of small molecules and large molecules: immunology and inflammation; oncology; cardiovascular and metabolic diseases; neuroscience and pain; and vaccines. Other areas of focus include rare diseases and biosimilars (1).

Pfizer has several key drugs in late-stage development. Among the products are: palbociclib (PD-0332991), an oral and selective reversible inhibitor of the CDK 4 and 6 kinases for the treatment of patients with estrogen receptor-positive, human epidermal growth factor receptor (EGFR) 2-negative advanced breast cancer, recurrent advanced breast cancer, and high-risk early breast cancer; ALO-02, a Mu-type opioid receptor agonist for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time; and bococizumab (RN316) (PF-04950615), a monoclonal antibody that inhibits PCSK9 for the treatment of hyperlipidemia and prevention of cardiovascular events. Other late-stage products are: dacomitinib, a pan-HER tyrosine kinase inhibitor for the first-line treatment of patients with advanced non-small cell lung cancer with EGFR-activating mutations, which is being developed in collaboration with SFJ Pharmaceuticals Group; ertugliflozin (PF-04971729), an oral sodium-glucose cotransporter-2 inhibitor for the treatment of Type 2 diabetes, which is being developed in collaboration with Merck & Co., Inc.; inotuzumab ozogamicin, an antibody drug conjugate, consisting of an anti-CD22 monotherapy antibody linked to a cytotoxic agent, calicheamycin, for the treatment of acute lymphoblastic leukemia; MnB rLP2086 (PF-05212366), a prophylactic vaccine for prevention of Neisseria meningitidis serogroup B invasive disease in adolescents and young adults (ages 11-25);  PF-05280014, a potential biosimilar to trastuzumab, a monoclonal antibody that binds and inhibits HER2 for the treatment of HER2-positive breast cancer and gastric cancer; and tanezumab, an anti-nerve growth factor monoclonal antibody for the treatment of pain (on clinical hold) (1). 

Pfizer’s R&D facilities support operations globally, with a heavy concentration in North America. In 2013, Pfizer continued to streamline its R&D locations while also expanding its R&D presence in Cambridge, Massachusetts. After the acquisition of Wyeth in 2009, Pfizer operated 20 R&D sites and has since then completed a number of site closures, including its Sandwich, UK R&D facility, except for a small presence. In addition, in 2011, the company rationalized several other sites to reduce and optimize its overall R&D footprint by disposing of its toxicology site in Catania, Italy; exiting R&D sites in Aberdeen and Gosport, UK; and disposing of a vacant site in St. Louis, Missouri while still maintaining biologics laboratories there (1). 

AstraZeneca: In 2013, AstraZeneca spent $4.269 billion on R&D, slightly down from the $4.291 billion spent in 2012. As of year-end 2013, AstraZeneca had 99 pipeline projects, including 85 in clinical development and 14 either approved, launched or filed. Its pipeline included 11 new molecular entities (NMEs) in Phase III development or under regulatory review, which the company said was almost double the amount compared with 2012 and which achieved its 2016 target volume almost three years ahead of schedule. Four NMEs were in Phase III development: benralizumab, a humanized monoclonal antibody being developed for the treatment of asthma; selumetinib, a small-molecule anticancer drug; olaparib, a small-molecule anticancer drug; and moxetumomab pasudotox, a monoclonal antibody anticancer drug (2). 

In June 2013, AstraZeneca announced that Cambridge, United Kingdom will be the location for the company’s new UK-based global R&D center and corporate headquarters. The new £330 million ($555 million) facility in Cambridge will bring together AstraZeneca’s small-molecule and biologics R&D activity. The purpose-built facility, which will be located in the Cambridge Biomedical Campus, is part of the company’s previously announced plan to create strategic global R&D centers in the UK (Cambridge), US (Gaithersburg, Maryland), and Sweden (Mölndal) by 2016 (2). In March 2014, the company announced the sale of its Alderley Park site in Cheshire, UK, to Manchester Science Parks (MSP), a Greater Manchester based public-private partnership and science park operator. The handover of the site will be phased over a three-year period, with the full exit of AstraZeneca R&D staff to take place in line with the completion of the company’s new facility in Cambridge. And in March 2014, AstraZeneca and UK’s Medical Research Council (MRC) formed a collaboration that will result in a new research facility to be built at AstraZeneca’s new R&D center in Cambridge, UK.

Currently, AstraZeneca has 9,000 employees in its R&D organization across 11 principal sites in six countries. Its R&D geographic footprint includes four main small-molecule facilities in the UK (Alderley Park and Macclesfield), Sweden (Mölndal), and the US (Waltham, Massachusetts). It also has  a clinical development facility in Japan (Osaka). Its current principal sites for biologics R&D are in the US (Gaithersburg, Maryland and Mountain View, California) and in the UK (Cambridge). Its Wilmington, Delaware site in the US focuses on late-stage development across the entire therapeutic portfolio. It also has a research facility in China (Shanghai), and in January 2014, the company announced plans to close its R&D site in India (Bangalore) (2).

  Table III: Proposed Combination of AstraZeneca and Pfizer, Global Established Products





 Therapeutic Area  Pfizer  AstraZeneca
 Primary & Specialty Care
 Assets
 Lipitor (atorvastatin calcium),
 Celebrex (celecoxib)
 Symbicort 
 (budesonide/formoterol 
 fumarate dehydrate)

 Viagra (sildenafil citrate) (ex-US),
 Revatio (sildenafil citrate)
 Pulmicort (budesonide)

 Lyrica (pregabalin) (EU),
 Pristiq (desvenlafaxine)
 Crestor (rosuvastatin calcium)
   Aricept (donepezil),
 Spiriva (tiotropium bromide 
 inhalation powder),
 Caduet (amlodipine 
 besylate/atorvastatin calcium)
 Seroquel XR (quetiapine 
 fumarate)
   Detrol (tolterodine),
 Inspra (eplerenone),
 Vfend (voriconazole)
 Zoladex (goserelin)
   Zyvox (linezolid),
 Tygacil (tigecycline)
 Arimidex (anastrozole)
   Xala brands,
 Geodon (ziprasidone)
 Casodex (bicalutamide)
   EpiPen (epinephrine),
 Premarin (conjugated estrogens)
 Merrem (meropenem)
     Zinforo (ceftaroline fosamil)

 Therapeutic Area  Pfizer  AstraZeneca
 Biosimilars  Monoclonal antibodies  

 Therapeutic Area  Pfizer  AstraZeneca
 Growth Initiatives / Pipeline  Solid Oral Dose Other respiratory pipeline

 Sterile Injectables  Benralizumab*

 Branded Value Offering
 (Hisun, Teuto, Mylan)**
 Tralokinumab*

Quillivant (methyphenidate HCl)
PT003 / PT001*
    CAZ-AVI*


CXL

 

 Therapeutic Area  Pfizer  AstraZeneca
 Legacy Brands  Norvasc (amlodipine), 
 Cardura (doxazosin)
 Prilosec (omeprazole)

 Zoloft (sertraline),
 Neurontin (gabapentin)
 Atacand (candesartan)

 Camptosar (irinotecan), 
 Aromasin (exemestane)
 Toprol (metoprolol succinate)/ 
 Seloken (metoprolol succinate)
   Medrol (methylprednisolone), 
 Sulperazon
 Seroquel (quetiapine fumarate)
   Sermion (nicergoline),
 Ativan (lorazepam)
 Xanax (alprazolam)
 Nexium (esomeprazole 
 magnesium)
   Protonix (pantoprazole), 
 Effexor (venlafaxine)
 

*Note: Phase III and registration programs denoted by asterisk. Only includes select commercial and development programs. 

**In 2012, Pfizer and Zhejiang Hisun Pharmaceuticals, a Chinese pharmaceutical company. formed Hisun-Pfizer Pharmaceuticals Co., Ltd., a joint venture formed between the two companies to develop, manufacture, and commercialize off-patent pharmaceutical products in China and global markets.

In 2010, Pfizer formed a partnership and acquired a 40% stake in the Brazilian generic-drug company Laboratorio Teuto Brasileiro S.A, with an option to acquire the remaining 60% in 2014. 

In 2012, Pfizer and Mylan formed a long-term strategic collaboration to develop, manufacture, distribute, and market generic drugs in Japan. 

Source: Pfizer

 

Manufacturing
Pfizer. Pfizer Global Supply (PGS) Division is headquartered in various locations, with leadership teams primarily in New York, New York and in Peapack, New Jersey. As of the end of 2013, PGS operated 56 plants. Locations with major manufacturing facilities include Belgium, China, Germany, Ireland, Italy, Japan, Puerto Rico, Singapore, and the US. After the acquisition of Wyeth in 2009, Pfizer manufacturing sites totaled 59. Other acquisitions added eight manufacturing sites, and the company subsequently exited 11 sites, resulting in 56 sites supporting continuing operations as of December 31, 2013. The company’s plant network strategy is expected to result in the exit of a further eight sites over the next several years. These site counts exclude five Nutrition business-related manufacturing sites as the Nutrition business was sold in 2012, and also exclude 24 Zoetis (Pfizer’s former animal-health business) sites as the disposition of Pfizer’s remaining 80.2% interest in Zoetis common stock was completed on June 24, 2013 (1).

AstraZeneca. AstraZeneca employs 8,700 people at 24 sites in 17 countries as part of its manufacturing and supply operations (2). Its principal small-molecule manufacturing facilities are in the UK (Avlon and Macclesfield), Sweden (Gärtuna and Södertälje), the US (Newark, Delaware and Westborough, Massachusetts), China (Wuxi and Taizhou), Russia (Vorsino), France (Reims and Dunkerque), Japan (Maihara), Australia (North Ryde), Indonesia (Jakarta), Egypt (Cairo), India (Bangalore), Puerto Rico(Canóvanas), Germany (Wedel), Mexico (Lomas Verdes), Brazil (Cotia), and Argentina (Buenos Aires). As of year-end 2013, it operated sites for the manufacture of APIs in the UK and Sweden, complemented by external sourcing. Its principal tablet and capsule formulation sites are in the UK, Sweden, Puerto Rico, and the US. It also has major formulation sites for the global supply of parenteral and/or inhalation products in Sweden, France, Australia, and the UK. For biologics, its four principal commercial manufacturing facilities are in the US (Frederick, Maryland and Philadelphia,Pennsylvania), the UK (Speke), and the Netherlands (Nijmegen) with capabilities in process development, manufacturing, and distribution of biologics, including supply of monoclonal antibodies and influenza vaccines (2).

In 2013, the company progressed two key production facilities, one in China (Taizhou), its second facility in the country, and one in Russia (Vorsino), which will enable the company to better supply products to both markets locally. These sites are intended to commence phased commercial production in 2014/2015. In 2013, AstraZeneca also announced plans to invest $190 million to construct a new facility at its Macclesfield (UK) facility by 2017 to continue production of the anticancer drug Zoladex (goserelin) (2).

References
1. Pfizer, 2013 Annual Filing 10-K (US Securities and Exchange Commission).  
2.AstraZeneca, 2013 Annual Filing 20-F (US Securities and Exchange Commission). 

0 comments
1476 views


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription 

Permalink